FusionPharm, Inc.
FSPM
$0.0001
$0.000.00%
| 03/31/2012 | 03/31/2011 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 793.75% | 212.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1,157.03% | 204.76% | |||
| Operating Income | -596.09% | -236.84% | |||
| Income Before Tax | -596.09% | -126.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -596.09% | -126.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -596.09% | -126.18% | |||
| EBIT | -596.09% | -236.84% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -167.57% | -- | |||
| Normalized Basic EPS | -165.59% | -- | |||
| EPS Diluted | -167.57% | -- | |||
| Normalized Diluted EPS | -165.59% | -- | |||
| Average Basic Shares Outstanding | 161.80% | -- | |||
| Average Diluted Shares Outstanding | 161.80% | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
